Screening of investigational agents through the ninds preclinical screening platform for pain (pspp)
Active Awarded Last action
- Contract number
- 75N95024F00001
- Awardee
-
Psychogenics Inc. UEI YXMNA8N7LFG4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $36,035,836
Award facts
- Opportunity
-
- NINDS Preclinical Screening Platform for Pain (PSPP) Pre-Solicitation · 75N95024R00054 · Posted Apr 2, 2024
- Contract value 55% obligated
-
- $36,035,836.00 Current, with exercised options
- $65,840,279.00 Potential, with all options
- Completion date 43% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Paramus, NJ 07652, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $14,781,625 | |
| Exercise an Option | $9,482,040 | |
| Original award | $11,772,171 |
About this award
The National Institute of Neurological Disorders and Stroke issued a $65.84 million delivery order to Psychogenics Inc. on September 6, 2024, under an $80 million Indefinite Delivery Contract for the Preclinical Screening Platform for Pain (PSPP).
The parent IDC supports NINDS's Helping to End Addiction Long-term (HEAL) initiative, enabling comprehensive screening of investigational agents across multiple pain models to identify potential non-addictive pain treatments. Work is performed in Paramus, New Jersey, with an ultimate completion date of September 5, 2029. The order is priced on a cost-plus-fixed-fee basis and is set aside for Total Small Business.
Psychogenics provides preclinical drug discovery and screening services using advanced technological platforms including SmartCube and eCube for in-vitro and in-vivo testing, evaluating investigational agents' efficacy, pharmacokinetics, side effects, and abuse liability across complex disease models.
Quick answers
Who was awarded contract 75N95024F00001?
75N95024F00001 was awarded to Psychogenics Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 6, 2024.
How much is contract 75N95024F00001 worth?
The government has obligated $36,035,836 on 75N95024F00001. Its potential value, with all options, is $65,840,279.
Which agency awarded contract 75N95024F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95024F00001, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95024F00001 an order under another contract?
Yes. 75N95024F00001 is a delivery order under 75N95024D00038, an indefinite delivery contract.
Was contract 75N95024F00001 competed?
The extent of competition for 75N95024F00001 was full and open competition after exclusion of sources. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award